Overview
Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.
LATEST PRESS RELEASES
03 May 2021 Regulatory
Kallelse till årsstämma i Stayble Therapeutics AB
Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning 6 i Göteborg. Inregistrering till...
03 May 2021 Regulatory
Stayble publishes the Annual Report for 2020
Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*....
LATEST FINANCIAL REPORTS
FINANCIAL CALENDAR
Interim report Q1 2021
17May2021
Annual meeting 2021
2June2021
Interim report Q2 2021
16August2021
Interim report Q3 2021
18November2021
